Histone deacetylase inhibitors: novel anticancer agents

Bibliography

• PENNISI E: Linker histones, DNA's protein custodians, gain new respect. Science (1996) 274:503–504.
   PubMed Web of Science ®Google Scholar
• WOLFFE AP: Sinful repression. Nature (1997) 387:16–17.
   PubMed Web of Science ®Google Scholar
• STRUHL K: Histone acetylation and transcriptional regulatory mechanisms. Genes & Develop. (1998) 12:599–606.
   PubMed Web of Science ®Google Scholar
• MIZZEN CA, YANG XJ, KOKUBO T et al.: The TAF11250subunit of TFIID has histone acetyltransferase activity. Cell (1996) 87:1261–1270.
   PubMed Web of Science ®Google Scholar
• OGRYZKO W, SCHILTZ L, RUSSANOVA V, HOWARD BHAND NAKATANI Y: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell (1996) 87:953-959. BANNISTER AJ, KOUZARIDES T: The CBP co-activator is a histone acetyltransferase. Nature (1996) 384:641-643. SIDDIQUE H, ZOU JP, RAO VN, REDDY ESP: The BRCA2 is a histone acetyltransferase. Oncogene (1998) 16:2283–2285.
   Google Scholar
• YANG XJ, OGRYZKO VV, NISHIKAWA J, HOWARD BH,NAKATANI Y: A p300/CBP-associated factor that competes with the adenoviral oncoprotein ElA. Nature (1996) 382:319–324.
   PubMed Web of Science ®Google Scholar
• TAUNTON J, HASSIG CA, SCHREIBER SL: A mammalianhistone deacetylase related to the yeast transcriptional regulator Rpd3p. Science (1996) 272:408–411.
   PubMed Web of Science ®Google Scholar
• YANG WM, YAO YL, SUN JM, DAVIE JR, SETO E: Isolationand characterisation of cDNA's corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. (1997) 272:28001–28007.
   PubMed Web of Science ®Google Scholar
• EMILIANI S, WOLFGANG F, VAN LINT C, AL-ABED Y,VERDIN E: Characterisation of a human RPD3, HDAC3. Proc. Natl. Acad. Sci. USA (1998) 95:2795–2800.
   PubMed Web of Science ®Google Scholar
• GROZINGER CM, HASSIG CA, SCHREIBER SL: Threeproteins define a class of human histone deacetylases related to yeast Hdalp. Proc. Natl. Acad. ScL USA (1999) 96:4868–4873.
   PubMed Web of Science ®Google Scholar
• CAMERON EE, BACHMAN KE, MYOHANEN S, HERMANJG, BAYLIN SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. (1999) 21:103–107.
   PubMed Web of Science ®Google Scholar
• •This manuscript integrates transcriptional silencing and histone acetylation into a simple model explaining transcription.
   Google Scholar
• JIN S, SCOTTO KW: Transcriptional regulation of theMDR1 gene by histone acetyltransferase and deacety-lase is mediated by NF-Y. Mol. Cell. Biol. (1998) 18 (7):4377–4384.
   PubMed Web of Science ®Google Scholar
• NAGY L, KAO HY, CHAKRAVARTI D et al.: Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (1997) 89:373–380.
   PubMed Web of Science ®Google Scholar
• HEINZEL T, LAVINSKY RM, MULLEN TM et al.: A complexcontaining N-CoR, msin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 387:43–48.
   PubMed Web of Science ®Google Scholar
• PAZIN MJ, KADONAGA JT: What's up and down withhistone deacetylation and transcription. Cell (1997) 89:325–326.
   PubMed Web of Science ®Google Scholar
• HASSIG CA, FLEISCHER TC, BILLIN AN, SCHREIBER SL,AYER DE: Histone deacetylase is required for full transcriptional repression by mSin3A. Cell (1997) 89:341–347.
   PubMed Web of Science ®Google Scholar
• LAHERTY CD, YANG WM, SUN JM, DAVIE JR, SETO E,EISENMAN RN: Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell (1997) 89:349–356.
   PubMed Web of Science ®Google Scholar
• HASSIG CA, TONG JK, SCHREIBER SL: Fiber-derived butyrate and the prevention of colon cancer. Chem. Biol. (1997) 4:783–789.
   PubMed Web of Science ®Google Scholar
• ARCHER SY, HODIN RA: Histone acetylation and cancer. Curr. Opin. Genetics Develop. (1999) 9:171–174.
   PubMed Web of Science ®Google Scholar
• MCBAIN JA, EASTMAN A, NOBEL CS, MUELLER GC: Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem. Pharmacol (1997) 53:1357–1368.
   PubMed Web of Science ®Google Scholar
• KAMINE J, ELANGOVEN B, SUBRAMANIAN T, COLEMAN D, CHINNADURAI G: Identification of a cellular protein that specifically interacts with the essential cystein region of the 11IV-1 tat transactivator. Virology (1996) 216:37–366.
   Web of Science ®Google Scholar
• SOBUTO OM, BORROW J, TOMEK R et al.: MLL is fused toCBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Nati Acad. Sci. USA (1997) 94:8732–8737.
   Google Scholar
• MURAOKA M, KONISHI M, KIKUCHI-YANOSHITA R et al.:p300 gene alterations in colorectal and gastric carcinomas. Oncogene (1996) 12:1565–1569.
   PubMed Web of Science ®Google Scholar
• GILES RH, PETERS DJM, BREUNING MH: Conjunction dysfunctions: CBP/p300 in human disease. Trends Genet. (1998) 14:178–183.
   PubMed Web of Science ®Google Scholar
• BREHM A, MISKA EA, MCCANCE DJ, REID JL, BANNISTERAJ, KOUZARIDES T: Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 391:597–601.
   PubMed Web of Science ®Google Scholar
• HE LZ, GUIDEZ F, TRIBIOLI C et al.: Distinct interactionsof PML-RARa and PLZF-RARa with co-repressors determine differential responses to RA in APL. Nature Genetics (1998) 18:126–135.
   PubMed Web of Science ®Google Scholar
• GRIGNANI F, DE MATTEIS S, NERVI C et al.: Fusionproteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 391 :815–818.
   PubMed Web of Science ®Google Scholar
• LIN RJ, NAGY L, INOUE S, SHAO W, MILLER WH, EVANS RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 391:811–814.
   PubMed Web of Science ®Google Scholar
• STRAUSS M, LUKAS J, BARTEK J: Unrestricted cell cycling and cancer. Nature Med (1995) 1:1245–1246.
   PubMed Web of Science ®Google Scholar
• WEINBERG RA: The retinoblastoma protein and cell cycle control. Cell (1995) 81(3):323–330.
   PubMed Web of Science ®Google Scholar
• SAUNDERS NA, FRAZER IH: Human Papilloma Virus. simplifying the molecular mechanisms of HPV. In Dermatologic Clinics. Freedman D (Ed.), WB Saunders and Co., USA. (1998):823–828.
   Google Scholar
• JONES SJ, DICKER AJ, DAHLER AL, SAUNDERS NA: E2F asa regulator of keratinocyte proliferation: implications for skin tumour development. J. Invest. Dermatol. (1997) 109:187–193.
   PubMed Web of Science ®Google Scholar
• MAGNAGHI-JAULIN L, GROISMAN R, NAGUIBNEVA I etRetinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature (1998) 391:601–605.
   PubMed Web of Science ®Google Scholar
• LUO RX, POSTIGIGO AA, DEAN DC: Rb interacts withhistone deacetylase to repress transcription. Cell (1998) 92:463–473.
   PubMed Web of Science ®Google Scholar
• BREHM A, NIELSEN SJ, MISKA EA et al. The E7 oncopro- tein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J (1999) 18(9):2449–2458.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M, HORINOUCHI S, BEPPU T: Trichostatin Aand trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays (1995) 17(5)423–430.
   Google Scholar
• PARSONS PG, HANSEN C, FAIRLIE DP et al.: Tumorselectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem. Pharmacol. (1997) 53:1719–1724.
   PubMed Web of Science ®Google Scholar
• RICHON VM, EMILIANI S, VERDINI E et al.: A class ofhybrid polar inducers of transformed cell differentia-tion inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA (1998) 95:3003–3007.
   PubMed Web of Science ®Google Scholar
• •Describes a new class of histone deacetylase inhibitors that are active in vitro and in vivo.
   Google Scholar
• DARKIN-RATTRAY SJ, GURNETT AM, MYERS RW et al.:Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA (1996) 93:13143–13147.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA H, KIM YB, TERANO H, YOSHIDA M, HORINOUCHI S: FR901228, a potent antitumor antibi-otic, is a novel histone deacetylase inhibitor. Exp. Cell Res. (1998) 241:126–133.
   PubMed Web of Science ®Google Scholar
• •Describes a new class of histone deacetylase inhibitors that are active in vitro and in vivo.
   Google Scholar
• SAITO A, YAMASHITA T, MARIKO Y et al.: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA (1999) 96:4592–4597.
   PubMed Web of Science ®Google Scholar
• •Describes a new class of histone deacetylase inhibitors that are active in vitro and in vivo.
   Google Scholar
• KIM YB, LEE KH, SUGITA K, YOSHIDA M, HORINOUCHI S: Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 18:2461–2470.
   PubMed Web of Science ®Google Scholar
• •Describes a new class of histone deacetylase inhibitors that are active in vitro and in vivo.
   Google Scholar
• KWON HJ, OWA T, HASSIG CA, SHIMADA J, SCHREIBER SL: Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc. Natl. Acad. Sci. USA (1998) 95:3356–3361.
   PubMed Web of Science ®Google Scholar
• •Describes a new class of histone deacetylase inhibitors that are active in vitro and in vivo.
   Google Scholar
• QIU L, KELSO MJ, HANSEN C, WEST ML, FAIRLIE DP, PARSONS PG: Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxa-mate. Br. J. Cancer (1999) 80 (8) : 1252–1258.
   PubMed Web of Science ®Google Scholar
• •Describes a new class of histone deacetylase inhibitors that are active in vitro, in vivo. This manuscript also shows some of the agents to be tumour-specific killers compared with non-transformed cells.V © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(10)
   Google Scholar
• SAUNDERS N, DICKER A, POPA C, JONES S, DAHLER A: Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. (1999) 59:399–404.
   PubMed Web of Science ®Google Scholar
• •This manuscript reports on the ability of HDAC inhibitors to irreversibly inhibit skin cancer cell growth.
   Google Scholar
• JANSON W, BRANDNER G, SIEGEL J: Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis. Oncogene (1997) 15:1395–1406.
   PubMed Web of Science ®Google Scholar
• HEERDT BG, HOUSTON MA, AUGENLICHT LH: Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell Growth and Differ. (1997) 8:523–532.
   PubMedGoogle Scholar
• DANGOND F, GULLANS SR: Differential expression ofhuman histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem. Biophys. Res. Comm. (1998) 247:833–837.
   PubMed Web of Science ®Google Scholar
• HUANG H, REED CP, ZHANG JS, SHRIDAR V, WANG L,SMITH DI: Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res. (1999) 59:2981–2988.
   PubMed Web of Science ®Google Scholar
• GILENWATER A, XU XC, ESTROV Y, SACKS PG, LOTAN D,LOTAN R: Modulation of galectin-1 content in human head and neck squamous carcinoma cells by sodium butyrate. Int. J. Cancer (1998) 75:217–224.
   PubMed Web of Science ®Google Scholar
• WANG J, SAUNTHARARAJAH Y, REDNER RL, LIU JM: Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. (1999) 59:2766–2769.
   PubMed Web of Science ®Google Scholar
• STAIANO-COICO L, STEINBERG M, HIGGINS PJ:Epidermal cell-shape regulation and subpopulation kinetics during butyrate-induced terminal maturation of normal and SV40-transformed human keratino-cytes: epithelial models of differentiation therapy. Int. J. Cancer (1990) 46:733–738.
   PubMed Web of Science ®Google Scholar
• SOWA Y, ORITA T, MINAMIKAWA S et al: Histone deacetylase inhibitor activates the WAF1/Cipl gene promoter through the Spl sites. Biochem. Biophys. Res. Comm. (1997) 241:142–150.
   PubMed Web of Science ®Google Scholar
• ARCHER SY, MENG S, SHEL A, HODIN RA: p21wAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA (1998) 95:6791–6796.
   PubMed Web of Science ®Google Scholar
• XIAO H, HASEGAWA T, ISOBE KI: Both Spl and Sp3 are responsible for p21'11 promoter activity induced by histone deacetylase inhibitor in NI113T3 cells. J. Cell. Biochem. (1999) 73:291–302.
   PubMed Web of Science ®Google Scholar
• DOETZLHOFER A, ROTHENEDER H, LAGGER G et al.: Histone deacetylase 1 can repress transcription by binding to Spl. Mol. Cell. Biol. (1999) 19(8):5504–5511.
   PubMed Web of Science ®Google Scholar
• NEWMARK HL, LUPTON JR, YOUNG CW: Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Lett. (1994) 78:1–5.
   PubMed Web of Science ®Google Scholar
• COLLINS AF, PEARSON HA, GIARDINA P, MCDONAGH KT, BRUSILOW SW, DOVER GJ: Oral sodium phenylabu-tyrate therapy in homozygous 13 thalassemia: a clinical trial. Blood 85(0:43–49.
   Google Scholar
• WARRELL RP, HE LZ, RICHON V, CALLEJA E, PANDOLFI PP: Therapeutic targetting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. (1998) 90(20:1621–1625.
   PubMedGoogle Scholar
• ••This is the first manuscript reporting a remission in a patientwith leukaemia mediated by combination therapy with an HDAC inhibitor plus a retinoid.
   Google Scholar
• CARDUCCI M, BOWLING MK, EISENBERGER M et al.: Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacologic evaluation of intrave-nous and oral PB. AntiCancer Res. (1997) 17:3972–3973.
   Google Scholar
• GORE SD, MILER CB, WENG LJ et al.: Clinical develop-ment of sodium phenylbutyrate (SPB) as a putative differentiating agent in myeloid malignancies. AntiCancer Res. (1997) 17:3938.
   Google Scholar
• SAMID D: Re: therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Nad Cancer Inst. (1999) 91(5)475–476.
   Google Scholar
• CHEN WY, BAILEY EC, MCCUNE SL, DONG JY, TOWNES TM: Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. Proc. Natl. Acad. Sci. USA (1997) 94:5798–5803.
   PubMed Web of Science ®Google Scholar